Risk factors associated with asbestos-related diseases: results of the asbestos surveillance programme Aachen

The aim of this study was to examine the association between workplace exposure to asbestos and risk factors for developing related chronic respiratory diseases, using the analysis of a cohort of 8,582 formerly asbestos-exposed workers, as well as to assess the grade value of three risk categories used for a focused surveillance procedure. The results showed that the participants who were aged over 65 (OR and 95% CI: 11.47 [5.48-23.99]) and active smokers (OR and 95% CI: 9.48 [4.07-22.09]), were at a significantly high risk for developing lung cancer. The risk of developing benign lesions of the lung or pleura (BLLP) was almost 6-times higher (OR and 95% CI: 5.76 [4.7-7]) for the age group over 65. The risk of developing mesothelioma was influenced by exposure duration (OR and 95% CI: 4.36 [1-19.01]); and for the age group over 65 (OR and 95% CI: 4.58 [1.86-11.27]). The study has demonstrated that the use of risk categories based on a combination of risk factors (age, smoking status, and duration of exposure) could be advantageous for planning the target health surveillance programmes

The local star-formation rate density: assessing calibrations using [OII], Ha and UV luminosities

We explore the use of simple star-formation rate (SFR) indicators (such as may be used in high-redshift galaxy surveys) in the local Universe using [OII], Ha, and u-band luminosities from the deeper 275 deg^2 Stripe 82 subsample of the Sloan Digital Sky Survey (SDSS) coupled with UV data from the Galaxy Evolution EXplorer satellite (GALEX). We examine the consistency of such methods using the star-formation rate density (SFRD) as a function of stellar mass in this local volume, and quantify the accuracy of corrections for dust and metallicity on the various indicators. Rest-frame u-band promises to be a particularly good SFR estimator for high redshift studies since it does not require a particularly large or sensitive extinction correction, yet yields results broadly consistent with more observationally expensive methods. We suggest that the [OII]-derived SFR, commonly used at higher redshifts (z~1), can be used to reliably estimate SFRs for ensembles of galaxies, but for high mass galaxies (log(M*/Msun)>10), a larger correction than is typically used is required to compensate for the effects of metallicity dependence and dust extinction. We provide a new empirical mass-dependent correction for the [OII]-SFR.Comment: 22 pages, 16 figures. This version corrects typos in equations 2, 7, and 9 of the published version, as described in the MNRAS Erratum. Published results are unaffected. A simple piece of IDL Code for applying the mass-dependent correction to [OII] SFR available from http://astro.uwaterloo.ca/~dgilbank/data/corroii.pr

Clinical performance and radiation dosimetry of no-carrier-added vs carrier-added 123I-metaiodobenzylguanidine (MIBG) for the assessment of cardiac sympathetic nerve activity

Purpose We hypothesized that assessment of myocardial sympathetic activity with no-carrier-added (nca) I-123-metaiodobenzylguanidine (MIBG) compared to carrier-added (ca) I-123-MIBG would lead to an improvement of clinical performance without major differences in radiation dosimetry. Methods In nine healthy volunteers, 15 min and 4 h planar thoracic scintigrams and conjugate whole-body scans were performed up to 48 h following intravenous injection of 185 MBq I-123-MIBG. The subjects were given both nca and ca I-123-MIBG. Early heart/mediastinal ratios (H/M), late H/M ratios and myocardial washout were calculated. The fraction of administered activity in ten source organs was quantified from the attenuation-corrected geometric mean counts in conjugate views. Radiation-absorbed doses were estimated with OLINDA/EXM software. Results Both early and late H/M were higher for nca I-123-MIBG (ca I-123-MIBG early H/M 2.46 +/- 0.15 vs nca I-123-MIBG 2.84 +/- 0.15, p = 0.001 and ca I-123-MIBG late H/M 2.69 +/- 0.14 vs nca I-123-MIBG 3.34 +/- 0.18, p = 0.002). Myocardial washout showed a longer retention time for nca I-123-MIBG (p <0.001). The effective dose equivalent (adult male model) for nca I-123-MIBG was similar to that for ca I-123-MIBG (0.025 +/- 0.002 mSv/MBq vs 0.026 +/- 0.002 mSv/MBq, p = 0.055, respectively). Conclusion No-carrier-added I-123-MIBG yields a higher relative myocardial uptake and is associated with a higher myocardial retention. This difference between nca I-123-MIBG and ca I-123-MIBG in myocardial uptake did not result in major differences in estimated absorbed doses. Therefore, nca I-123-MIBG is to be preferred over ca I-123-MIBG for the assessment of cardiac sympathetic activit

Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study

Purpose: Adequate patient allocation is pivotal for optimal resource management in strained healthcare systems, and requires detailed knowledge of clinical and virological disease trajectories. The purpose of this work was to identify risk factors associated with need for invasive mechanical ventilation (IMV), to analyse viral kinetics in patients with and without IMV and to provide a comprehensive description of clinical course. Methods: A cohort of 168 hospitalised adult COVID-19 patients enrolled in a prospective observational study at a large European tertiary care centre was analysed. Results: Forty-four per cent (71/161) of patients required invasive mechanical ventilation (IMV). Shorter duration of symptoms before admission (aOR 1.22 per day less, 95% CI 1.10-1.37, p < 0.01) and history of hypertension (aOR 5.55, 95% CI 2.00-16.82, p < 0.01) were associated with need for IMV. Patients on IMV had higher maximal concentrations, slower decline rates, and longer shedding of SARS-CoV-2 than non-IMV patients (33 days, IQR 26-46.75, vs 18 days, IQR 16-46.75, respectively, p < 0.01). Median duration of hospitalisation was 9 days (IQR 6-15.5) for non-IMV and 49.5 days (IQR 36.8-82.5) for IMV patients. Conclusions: Our results indicate a short duration of symptoms before admission as a risk factor for severe disease that merits further investigation and different viral load kinetics in severely affected patients. Median duration of hospitalisation of IMV patients was longer than described for acute respiratory distress syndrome unrelated to COVID-19

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease. Patients were randomly assigned to receive either evacetrapib at a dose of 130 mg or matching placebo, administered daily, in addition to standard medical therapy. The primary efficacy end point was the first occurrence of any component of the composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. RESULTS: At 3 months, a 31.1% decrease in the mean LDL cholesterol level was observed with evacetrapib versus a 6.0% increase with placebo, and a 133.2% increase in the mean HDL cholesterol level was seen with evacetrapib versus a 1.6% increase with placebo. After 1363 of the planned 1670 primary end-point events had occurred, the data and safety monitoring board recommended that the trial be terminated early because of a lack of efficacy. After a median of 26 months of evacetrapib or placebo, a primary end-point event occurred in 12.9% of the patients in the evacetrapib group and in 12.8% of those in the placebo group (hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.11; P=0.91). CONCLUSIONS: Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease. (Funded by Eli Lilly; ACCELERATE ClinicalTrials.gov number, NCT01687998 .)

Access Control to Information in Pervasive Computing Environments.

Abstract Pervasive computing envisions a world in which our environment is full of embedded devices that gather and share vast amounts of information about people, such as their location, activity, or even their feelings. Some of this information is confidential and should not be released to just anyone. In this thesis, I show how existing solutions for controlling access to information are not sufficient for pervasive computing because of four challenges: First, there will be many information services, potentially offering the same information, run by different organizations, even in a single social environment. Second, there will be complex types of information, such as a person&apos;s calendar entry, which reveal other kinds of information, such as the person&apos;s current location. Third, there will be services that derive specific information, such as a person&apos;s activity, from raw information, such as a videostream, and that become attractive targets for intruders. Fourth, an individual&apos;s ability to access information could be constrained based on confidential information about the individual&apos;s context. This thesis presents a distributed access-control architecture for pervasive computing that supports complex and derived information and confidential context-sensitive constraints. In particular, the thesis makes the following contributions: First, I introduce a distributed accesscontrol architecture, in which a client proves to a service that the client is authorized to access requested information. Second, I show how to incorporate the semantics of complex information as a first-class citizen into this architecture, based on information relationships. Third, I propose derivation-constrained access control, which reduces the influence of intruders by making a service prove that the service is accessing information on behalf of an authorized client. Fourth, I study the kinds of information leaks that context-sensitive constraints can cause. I introduce access-rights graphs and hidden constraints for avoiding these leaks. Fifth, I show how pervasive computing makes it difficult for a client to prove that the client is authorized to access complex confidential information. I propose a cryptographic solution based on an extension of hierarchical identity-based encryption. Sixth, as an alternative approach, I introduce an encryption-based access-control architecture for pervasive computing, in which a service gives information to any client, but only in an encrypted form. I present a formal model for my contributions based on Lampson et al.&apos;s theory of authentication. All of my contributions have been implemented in an actual pervasive computing environment. A performance analysis of my implementation demonstrates the feasibility of my design

Lung function not affected by asbestos exposure in workers with normal Computed Tomography scan

Background: It has been suggested that asbestos exposure affects lung function, even in the absence of asbestos-related pulmonary interstitial or pleural changes or emphysema. Methods: We analyzed associations between well-known asbestos-related risk factors, such as individual cumulative asbestos exposure, and key lung function parameters in formerly asbestos-exposed power industry workers (N=207) with normal CT scans. For this, we excluded participants with emphysema, fibrosis, pleural changes, or any combination of these. Results: The lung function parameters of FVC, FEV1, DLCO/VA, and airway resistance were significantly associated with the burden of smoking, BMI and years since end of exposure (only DLCO/VA). However, they were not affected by factors directly related to amount (eg, cumulative exposure) or duration of asbestos exposure. Conclusions: Our results confirm the well-known correlation between lung function, smoking habits, and BMI. However, we found no significant association between lung function and asbestos exposure.</p